Protagenic Therapeutics, Inc. (PTIX) Earnings History
Net Loss31 years of earnings data (1995–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Protagenic Therapeutics, Inc. (PTIX) Earnings Overview
As of June 29, 2026, Protagenic Therapeutics, Inc. (PTIX) reported trailing twelve-month net income of -$5M, reflecting -205.3% year-over-year growth. The company earned $-2.66 per diluted share over the past four quarters.
Looking at the long-term picture, PTIX's historical earnings data spans multiple years. The company achieved its highest annual net income of $1M in fiscal 2000.
Protagenic Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SAVA (-$106M net income), ATHA (-$129M net income), NRXP (-$25M net income, -2336.5% margin), PTIX has comparable earnings metrics. Compare PTIX vs SAVA →
PTIX Earnings vs Peers
Earnings metrics vs comparable public companies
PTIX Historical Earnings Data (1995–2025)
29 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$5M | +6.7% | -$6M | $-3.45 | - | - |
| 2024 | -$6M | -10.5% | -$6M | $-1.13 | - | - |
| 2023 | -$5M | -40.6% | -$5M | $-1.15 | - | - |
| 2022 | -$4M | +21.4% | -$4M | $-0.82 | - | - |
| 2021 | -$5M | -77.5% | -$4M | $-1.24 | - | - |
| 2020 | -$3M | -45.6% | -$3M | $-1.00 | - | - |
| 2019 | -$2M | +31.5% | -$2M | $-0.69 | - | - |
| 2018 | -$3M | -13.2% | -$2M | $-1.00 | - | - |
| 2017 | -$2M | +0.7% | -$2M | $-0.88 | - | - |
| 2016 | -$2M | -378.2% | -$2M | $-1.72 | - | - |
| 2015 | $-476,000 | +55.9% | $-491,000 | $-73.23 | - | - |
| 2014 | -$1M | -5.1% | $-975,000 | $-166.00 | - | - |
| 2013 | -$1M | +94.8% | $-673,000 | $-632.00 | -1208.2% | -791.8% |
| 2010 | -$20M | +33.1% | -$22M | $-193401.96 | -49.3% | -55.7% |
| 2009 | -$29M | +74.5% | -$29M | $-350833.33 | -42.7% | -41.8% |
| 2008 | -$116M | -2690.2% | -$117M | $-999999.00 | -101.7% | -102.8% |
| 2007 | -$4M | -712.9% | -$5M | $-84673.47 | -11.2% | -14.9% |
| 2006 | $677,000 | +816.6% | $1M | $677000.00 | 3.6% | 7.9% |
| 2005 | $-94,470 | +95.8% | $-94,470 | $-94470.00 | - | - |
| 2004 | -$2M | +71.7% | -$2M | $-0.53 | - | - |
| 2003 | -$8M | -985.2% | -$8M | $-1.86 | - | - |
| 2002 | $-728,000 | -605.6% | $-528,000 | $-728000.00 | -3.9% | -2.8% |
| 2001 | $144,000 | -87.3% | $747,000 | $144000.00 | 0.7% | 3.5% |
| 2000 | $1M | +268.5% | $2M | $999999.00 | 5.3% | 8.6% |
| 1999 | $-674,000 | -204.0% | $-275,000 | $-674000.00 | -3.6% | -1.5% |
| 1998 | $648,000 | +172.0% | $866,000 | $648000.00 | 4.1% | 5.5% |
| 1997 | $-900,000 | -200.0% | $-661,000 | $-858000.00 | -7.2% | -5.3% |
| 1996 | $-300,000 | +50.0% | $-700,000 | $-0.07 | -3.0% | -7.1% |
| 1995 | $-600,000 | - | -$1M | $-0.14 | -8.7% | -14.5% |
Download Data
Export PTIX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
31+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PTIX — Frequently Asked Questions
Quick answers to the most common questions about buying PTIX stock.
What is PTIX earnings per share (EPS)?
PTIX trailing twelve-month (TTM) diluted EPS is $-2.66, reflecting -205.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1995 to 2025 is available in the table on this page.
What is Protagenic Therapeutics, Inc.'s net income?
Protagenic Therapeutics, Inc. (PTIX) trailing twelve-month net income is $-5M as of 2025. Earnings declined -205.3% year-over-year.
Is PTIX profitable?
PTIX is not currently profitable on a TTM basis, reporting a net loss of $-5M. Net margin is N/A. Investors should monitor for a return to profitability.
What is PTIX's earnings growth rate?
PTIX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1995 to 2025.
What are PTIX's profit margins?
Protagenic Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is PTIX growing earnings?
PTIX earnings are declining — EPS fell -205.3% year-over-year. TTM net income dropped to $-5M. This contrasts with the 5-year CAGR of N/A.
What was PTIX's best earnings year?
Protagenic Therapeutics, Inc.'s highest annual net income on record is $1M, achieved in fiscal year 2000. Earnings history on this page spans 1995 to 2025 and includes all annual and quarterly figures.
What were PTIX's earnings last quarter?
PTIX's most recent reported quarter was Q4 2025. Net income was $2M with diluted EPS of $1.14. For a full breakdown of all quarters, see the quarterly earnings table on this page.